Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats[1].
Zenarestat (3.2, 32 mg/kg; p.o.; daily for 8 weeks) inhibits nerve sorbitol accumulation in a dose-dependent manner[1].
[1]. Shimoshige Y, et al. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats. Metabolism. 2000;49(11):1395-1399.